<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Honokiol, a component of the herb Magnolia officinalis, exhibits <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, anti-inflammatory and anxiolytic properties, increases <z:hpo ids='HP_0001250'>seizure</z:hpo> threshold, and promotes neurite outgrowth </plain></SENT>
<SENT sid="1" pm="."><plain>Because <z:hpo ids='HP_0001297'>stroke</z:hpo> has become the second leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> in industrialized countries, an effective neuroprotectant is urgently required </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we attempted to elucidate in a mouse <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> model whether honokiol could be a neuroprotectant </plain></SENT>
<SENT sid="3" pm="."><plain>Adult male Institute of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research (ICR) mice were subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 45 min </plain></SENT>
<SENT sid="4" pm="."><plain>Honokiol (10 microg/kg in 0.2 ml of saline) or control vehicle was intraperitoneally administered twice, 15 min. before and 60 min. after the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">Cerebral ischaemia</z:e> induced by this method was associated with an increase in synaptosomal production of reactive oxygen species, with decreases in synaptosomal <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential (DeltaPsim) and synaptosomal <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> metabolic function, and with reductions in <z:chebi fb="0" ids="29101">Na(+)</z:chebi>, <z:chebi fb="0" ids="29103">K(+)</z:chebi>-ATPase activities of tissues isolated from selected brain regions </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of honokiol resulted in significant reductions in brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and in synaptosomal production of reactive oxygen species </plain></SENT>
<SENT sid="7" pm="."><plain>The decreases in synaptosomal <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential, synaptosomal <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> metabolic function and tissue <z:chebi fb="0" ids="29101">Na(+)</z:chebi>, <z:chebi fb="0" ids="29103">K(+)</z:chebi>-ATPase activities observed in the ischaemic brains were also attenuated by honokiol treatments </plain></SENT>
<SENT sid="8" pm="."><plain>It is concluded that honokiol can protect brain against ischaemic reperfusion injury and preserve <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function from <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Regarding therapeutic application, further studies are needed to assess the efficacy and safety of honokiol in clinical situations </plain></SENT>
</text></document>